Intraperitoneal docetaxel for Peritoneal Carcinomatosis

Johns Hopkins University, Baltimore, MD
Peritoneal CarcinomatosisIntraperitoneal docetaxel - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new treatment for gastric cancer that has spread to the abdomen. The new treatment is a combination of two drugs, and this study will test how well it works.

Eligible Conditions
  • Peritoneal Carcinomatosis

Treatment Effectiveness

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 20 weeks

20 weeks
Maximum Tolerated Dose (MTD)
Progression-Free Survival

Trial Safety

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.

Trial Design

1 Treatment Group

Intraperitoneal docetaxel
1 of 1

Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: Intraperitoneal docetaxel · No Placebo Group · Phase 1

Intraperitoneal docetaxel
Experimental Group · 1 Intervention: Intraperitoneal docetaxel · Intervention Types: Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 20 weeks

Who is running the clinical trial?

Johns Hopkins UniversityLead Sponsor
2,115 Previous Clinical Trials
32,578,739 Total Patients Enrolled
Fabian M Johnston, MD, MHSPrincipal InvestigatorJohns Hopkins University
1 Previous Clinical Trials
310 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are willing to have a device called an intraperitoneal port placed in your body for the study.

Frequently Asked Questions

How many research participants are involved in this experiment?

"Affirmative. The information located on indicates that this research is presently searching for volunteers. This investigation was first posted to the website in November 1st 2020 and recently updated on November 7th 2022, with a goal of enlisting 30 patients from one single medical site." - Anonymous Online Contributor

Unverified Answer

Are there any other investigations that have employed Intraperitoneal docetaxel?

"Currently, 320 Intraperitoneal docetaxel trials are underway. 126 of them have reached the third phase of research and development. Most of these experiments originate in Fuzhou, Fujian; however, there are 22389 participating sites for this procedure worldwide." - Anonymous Online Contributor

Unverified Answer

What are the known risks of administering Intraperitoneal docetaxel to patients?

"Our experts at Power assigned an approximate safety rating of 1 to intraperitoneal docetaxel, as this is only a Phase 1 trial and there is limited data available on its efficacy or risk profile." - Anonymous Online Contributor

Unverified Answer

Are any fresh participants being admitted to this trial?

" confirms that this medical trial was first made public on November 1st 2020 and is currently recruiting participants. The listing of the study has been updated as recently as November 7th 2021." - Anonymous Online Contributor

Unverified Answer

What health issues is Intraperitoneal docetaxel commonly administered for?

"Intraperitoneal docetaxel is a widely used medication for the treatment of malignant cancerous growths. It can also be deployed to treat more specific conditions such as esophageal neoplasms, sarcoma, and advanced directives." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.